HDFC Pharma And Healthcare Fund

PLUS: Strong start, benchmark outperformance, quality sector exposure
✓ HDFC Pharma And Healthcare Fund has made a strong early impression, delivering 7.91% 1-year return, clearly ahead of both benchmark and category average.
✓ The fund has also ranked among the top performers in its category, which gives it early credibility within the healthcare/thematic space.
✓ Its portfolio mix across large-cap, mid-cap and small-cap healthcare names gives it a broader opportunity set rather than a plain large-cap pharma basket.
✓ Minimum SIP and investment starting at Rs. 100 makes it easy for investors to build exposure gradually through SIP instead of risky lump-sum entry.
✓ HDFC Mutual Fund’s strong research platform and fund house credibility add comfort in a specialised sector where stock selection matters a lot.

MINUS: New fund, expensive valuations, thematic concentration risk
⚖️ The biggest limitation is that this is still a relatively new fund, so there is no 3-year or 5-year consistency record yet.
⚖️ Portfolio concentration is meaningful, with Top 10 stocks at 62.52% and Top 3 sectors at 98.22%, which naturally raises thematic volatility risk.
⚖️ Valuations look rich with P/E of 49.22 and P/B of 6.47, meaning upside can remain sensitive to earnings misses or sector de-rating.
⚖️ This is still a sector fund, not a diversified core equity scheme — so investors should expect sharper swings and avoid over-allocation despite strong recent momentum.

Sahifund View (Decisive Line):

HDFC Pharma And Healthcare Fund looks like a strong high-conviction thematic SIP candidate, but it should remain a satellite bet and not a core portfolio hold